Novel Anti-inflammatory Effects of Canagliflozin Involving Hexokinase II in Lipopolysaccharide-Stimulated Human Coronary Artery Endothelial Cells

PURPOSE: Vascular inflammation and disturbed metabolism are observed in heart failure and type 2 diabetes mellitus. Glycolytic enzyme hexokinase II (HKII) is upregulated by inflammation. We hypothesized that SGLT2 inhibitors Canagliflozin (Cana), Empagliflozin (Empa) or Dapagliflozin (Dapa) reduces...

Descripción completa

Detalles Bibliográficos
Autores principales: Uthman, Laween, Kuschma, Marius, Römer, Gregor, Boomsma, Marleen, Kessler, Jens, Hermanides, Jeroen, Hollmann, Markus W., Preckel, Benedikt, Zuurbier, Coert J., Weber, Nina C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8578058/
https://www.ncbi.nlm.nih.gov/pubmed/33048256
http://dx.doi.org/10.1007/s10557-020-07083-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8578058/
https://www.ncbi.nlm.nih.gov/pubmed/33048256
http://dx.doi.org/10.1007/s10557-020-07083-w

Ejemplares similares